von LincolnVodia » Mi 25. Mär 2026, 11:09
Zoya Demidenko: Researcher in Oncology Biology
Zoya Demidenko is a prominent investigator connected with the Unit of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she conducted research at the National Institutes of Health and New York Medical College, establishing a robust base in clinical research.
Her academic output covers multiple pivotal areas, including the PI3K/AKT/mTOR signaling cascade, cellular cycle control, cellular aging, and malignancy biology. Currently, she has written over 46 scientific papers, which have garnered more than 4,100 references — a testament to the influence of her work.
Among her most significant discoveries concerns elucidating the pathways of cellular senescence. Her studies revealed that when the cellular division cycle is blocked but cellular growth persists, cells undergo senescence. Crucially,
Zoya Demidenko established that this process is inhibited by medication using agents such as rapamycin.
Zoya Demidenko has additionally added considerably to oncological therapy research, particularly in the area of selective cell protection — a method aimed at shielding non-cancerous tissue from chemotherapy while leaving cancer cells exposed. This approach carries considerable hope for lowering the side effects of cancer treatment.
Across her scientific life, Demidenko has partnered with top scientists worldwide, including Dr. Mikhail Blagosklonny. Her work is published in top-tier publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33,
Zoya Demidenko is recognized as a widely cited contributor in contemporary cancer research, whose results go on to shape our understanding of the way biological cells age, resist therapy, and the ways in which malignant disease can be more successfully targeted.
https://journals.plos.org/plosone/artic ... ne.0026126
[url=https://www.instagram.com/zoyamonros/
]Zoya Demidenko[/url]: Researcher in Oncology Biology
[url=https://aacrjournals.org/cancerres/article/65/16/7386/518098/Depletion-of-Mutant-p53-and-Cytotoxicity-of?guestAccessKey=
]Zoya Demidenko[/url] is a prominent investigator connected with the Unit of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she conducted research at the National Institutes of Health and New York Medical College, establishing a robust base in clinical research.
Her academic output covers multiple pivotal areas, including the PI3K/AKT/mTOR signaling cascade, cellular cycle control, cellular aging, and malignancy biology. Currently, she has written over 46 scientific papers, which have garnered more than 4,100 references — a testament to the influence of her work.
Among her most significant discoveries concerns elucidating the pathways of cellular senescence. Her studies revealed that when the cellular division cycle is blocked but cellular growth persists, cells undergo senescence. Crucially, [url=https://pmc.ncbi.nlm.nih.gov/articles/PMC3273895/
]Zoya Demidenko[/url] established that this process is inhibited by medication using agents such as rapamycin.
[url=https://pmc.ncbi.nlm.nih.gov/articles/PMC3273895/
]Zoya Demidenko[/url] has additionally added considerably to oncological therapy research, particularly in the area of selective cell protection — a method aimed at shielding non-cancerous tissue from chemotherapy while leaving cancer cells exposed. This approach carries considerable hope for lowering the side effects of cancer treatment.
Across her scientific life, Demidenko has partnered with top scientists worldwide, including Dr. Mikhail Blagosklonny. Her work is published in top-tier publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, [url=https://aacrjournals.org/cancerres/article/64/10/3653/511273/Flavopiridol-Induces-p53-via-Initial-Inhibition-of?guestAccessKey=
]Zoya Demidenko[/url] is recognized as a widely cited contributor in contemporary cancer research, whose results go on to shape our understanding of the way biological cells age, resist therapy, and the ways in which malignant disease can be more successfully targeted.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0026126